We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Silence Therapeutics Plc | LSE:SLN | London | Ordinary Share | GB00B9GTXM62 | ORD 5P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 535.00 | 521.00 | 524.00 | - | 0.00 | 00:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
21/9/2017 09:43 | Well this is all very nice. I thought the muted shareprice reaction to the alny news yesterday was rather strange - and but for what presumably was a very large seller feeding the buying interest I imagine we would have had a much stronger move yesterday. It will be good to see any holdings notices that come out of yesterday's volume. | 1gw | |
21/9/2017 05:51 | The recent director buys around 150p clearly aren't intended to make a 10%-20% gain. Likewise the last financing round at >200p. Everyone knows what the end game is here and I am expecting a nice steady rise up to 250-300p region ahead of the November capital markets day. Should be fun | rogen83 | |
20/9/2017 18:46 | ALNY or ARWR in would be interesting | djnzloop | |
20/9/2017 15:19 | Wouldn't be surprised if that's Woodford out | djnzloop | |
20/9/2017 13:30 | I've just bought some more at closer to 180 but thought I'd try to ride the "year of rnai" a bit further, having seen alny up 30% or so in the pre-market. | 1gw | |
20/9/2017 13:13 | It does seem that way. Bought a few at 170 but took awhile to execute so suspect is one seller via one broker and hence the delays? Edit: And there it is the rump 2.8m sold and off the share price goes | waterloo01 | |
20/9/2017 13:06 | I know the trade listings aren't always reliable, but given the volume going through at 170p and the spread it looks to me like there is a big supply available at 170p. i.e. an existing holder happy to sell the news and take profit at that price after the recent scare. | 1gw | |
20/9/2017 13:00 | What's the chances that any big cash influx to ALYN will lead to the suggested take out of SLN? | waterloo01 | |
20/9/2017 12:48 | A long wait of over 10 years....but great news. | benson384 | |
20/9/2017 12:43 | I think the most important aspect here, aside from any IP and licensing fees attributable to SLN is that this will be the first RNAi candidate to reach the stage of a commercial drug. This will give a huge lift to the valuations of the whole sector. Been waiting years for this. | callumross | |
20/9/2017 12:11 | who is buying all this stock at £1.70 , they obviously want it higher, on that basis i purchased a few to trade. | partner | |
20/9/2017 11:39 | Huge volume of automatic trades going through. | callumross | |
20/9/2017 11:20 | Probably be announcement from SLN later re this, given the IP case in the High Court. Makes you wonder if ALNY managed the newsflow earlier this month to get the disappointing news out first leaving the Patisiran news to be announced untarnished. | callumross | |
20/9/2017 11:10 | ALNY announces positive Patisiran results! “We are very proud to report the first ever positive Phase 3 results for an RNAi therapeutic, marking the potential arrival of an entirely new class of medicines. This moment is the culmination of a 15-year journey of tireless work by countless contributors who have overcome enormous scientific and business challenges to make RNAi therapeutics a reality,” said John Maraganore, Ph.D., Chief Executive Officer of Alnylam. “This is an incredibly exciting milestone for Alnylam and RNAi, and most importantly for patients and their treating physicians and families. We extend our deepest gratitude to all the patients, investigators and study staff who participated in the APOLLO study – they made this important scientific progress possible.” ased on these positive results, Alnylam expects to file its first New Drug Application in late 2017 and first Marketing Authorisation Application shortly thereafter. Sanofi Genzyme is currently preparing for regulatory filings for patisiran in Japan, Brazil and other countries, to begin in the first half of 2018. Pending regulatory approvals, Alnylam will commercialize patisiran in the U.S., Canada and Western Europe, with Sanofi Genzyme commercializing the product in the rest of the world. “This is a significant milestone that supports our belief that RNAi therapeutics have the potential to become an innovative new class of medicines for patients with rare genetic diseases,” said Elias Zerhouni, M.D., President, Global R&D, Sanofi | callumross | |
18/9/2017 14:00 | "Down to 125-130p on charts?" LOL! | callumross | |
18/9/2017 07:35 | Down to 125-130p on charts? | tsmith2 | |
15/9/2017 14:12 | But whether that's punters buying the dip or professionals taking a considered view of what was released yesterday I have no means of telling. So I remain out for now. Very grateful to Ali for highlighting it as an opportunity with the Silence release on their own acquisition but think I need it to fall back a lot closer to $2 before going back in. | 1gw | |
15/9/2017 14:09 | Yes - up big on huge volume. | 1gw | |
15/9/2017 13:48 | Arrowhead back up 10% in early trades! | callumross | |
15/9/2017 10:04 | As 1gw predicted the drop in ARWR last night was entirely predictable and not based on any adverse news in the presentation. SLN is giving up some of its recent gains. Happy to keep my core holding but might purchase a few as a cheeky trade in the weeks to come in the hope that there may be a ARWR type rise in the run up to SLN's presentation in mid-November. | callumross | |
15/9/2017 07:44 | 130 could get played out here, would represent attractive entry point. | tsmith2 | |
15/9/2017 07:42 | Arrowhead down a lot last night. | tsmith2 | |
14/9/2017 18:57 | Definitely some "sell on the news" going on just now in ARWR, so I've joined in and that's me out of ARWR for now. | 1gw |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions